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Hepatitis A is a vaccine-preventable disease with a global distribution. It predominantly occurs in 
regions with inadequate living conditions, but also affects populations in industrialised countries. 
Children are frequently involved in the transmission of hepatitis A virus (HAV) and thus play a central 
role in the epidemiology of hepatitis A. Here, we investigated HAV infections, immunisations, and 
associated demographic determinants in a nationwide, population-based, cross-sectional survey 
conducted in Germany from 2003–2006. Out of 17,640 children and adolescents, complete data sets 
(HAV serology, demographic information and vaccination card) were available for 12,249 (69%), all 
aged 3–17 years. We found protective antibody levels (>=20 IU/L) in 1,755 (14%) individuals, 1,395 
(11%) were vaccinated against hepatitis A, 360 (3%) individuals were HAV seropositive without prior 
hepatitis A vaccination, thus indicating a previous HAV infection. Antibody prevalence (attributable 
to vaccination or infection) increased significantly with age. Multivariate logistic regression revealed 
that predominantly children and adolescents with migration background–even if they were born 
in Germany–are affected by HAV infections. Our results provide a rationale to emphasise existing 
vaccination recommendations and, moreover, to consider additional groups with a higher risk of 
infection for targeted vaccination, especially children with a migration background.
Hepatitis A is a vaccine-preventable disease caused by the hepatitis A virus (HAV) which is transmitted mainly 
via the faecal-oral route through close personal contact or contaminated food and water1.
The course of disease is variable, ranging from mild gastrointestinal symptoms to a severe icteric illness lasting 
several months. In general, symptoms are more severe in the elderly and people with weakened immune system. 
Particularly patients with chronic liver diseases are at risk of developing fulminant hepatitis A with a possible 
fatal outcome2,3.
Even though HAV infections in children often remain subclinical, children nevertheless have a key role in the 
epidemiology of hepatitis A. Firstly, particularly young children do not have strong individual hygiene skills, thus 
facilitating transmission of HAV via the faecal-oral route. Secondly, in countries without universal childhood 
vaccination and with low HAV endemicity, children are usually not immune and thus highly susceptible to HAV 
infection. Moreover, due to the relatively high infectivity of HAV together with a low rate of HAV immunity 
(lack of herd immunity), the outbreak potential in children is significant. Thirdly, HAV infections in children 
are mainly mild or even asymptomatic but are still quite common, so that numerous infections can go unnoticed 
which further promotes the spread of HAV4–9.
HAV endemicity is largely dependent on socio-economic development and typically highest in regions with 
poor sanitation and without access to safe drinking water10–13. In addition, travel abroad and (imported) contam-
inated food products are confirmed sources of infection12,14,15. Although Germany is regarded as a country with 
low HAV endemicity, two-thirds of the reported cases of hepatitis A are due to autochthonous transmission16.
Available hepatitis A virus vaccines are safe and highly effective and employed for routine childhood vaccina-
tion programs in some parts of the world9,17–20.
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In Germany, the Standing Committee on Vaccination generally recommends vaccination for travellers to 
HAV-endemic areas but does not advocate universal childhood vaccination21.
Hence, elucidating factors associated with HAV infections, identifying vaccination gaps, and characterising 
groups at particular risk are important steps to further reduce HAV transmission.
To this end, we analysed HAV seroprevalence among German children and adolescents aged 3–17 years par-
ticipating in a nationwide, population-based, cross-sectional survey and investigated associated demographic 
factors consecutively in vaccinated and infected individuals.
Material and Methods
Study design. Our study was performed within the framework of the German KiGGS survey (“German 
Health Interview and Examination Survey for Children and Adolescents”), a nationwide, population-based, 
cross-sectional survey, conducted between 2003 and 2006. In brief, a two-staged cluster-sampling was applied. At 
the first stage, 167 sample points (municipalities) were randomly selected across Germany, followed by the second 
stage with a random selection of 8–10 children or adolescents per age group and sample point from the popula-
tion register, respectively22,23. Vaccination cards were requested from all participants. Serum samples (to test for 
anti-HAV antibodies) were available for participants aged 3 years and older. In order to be able to distinguish 
HAV seropositivity due to hepatitis A immunisation (>=1 shot of hepatitis A vaccine) and HAV infection, we 
focused on individuals having provided a vaccination card in addition to the serum sample. All other participants 
were excluded from the analysis. A weighting factor was introduced that corrects the sample’s deviations (sample 
with serum available) from the (German) population structure with regard to age, gender, region, nationality, 
type of municipality, and the education status of the head of the household.
Quantification of anti-HAV antibodies. Each serum sample (among participants aged 3–17 years) col-
lected within the framework of the German KiGGS survey was tested for total anti-HAV-antibody levels (IgM 
and IgG) by using an established quantitative immunoassay (Elecsys anti-HAV, Roche Diagnostics, Mannheim, 
Germany) according to the manufacturer’s instructions24,25. The detection range of the test is linear between titres 
of 3.0–60.0 IU/L. In accordance to the manufacturers’ instructions, sample titres <20.0 IU/L were classified as 
seronegative and titres >=20.0 IU/L seropositive, respectively. Of note, anti-HAV-IgG titres of 20.0 IU/L or above 
are commonly defined as protective4,26–31.
Statistical analysis. Statistical analysis was performed using STATA 13 software (StataCorp LP, College 
Station, TX, USA). In order to account for the cluster structure of the sampling method, sampling weights were 
used in the statistical analysis to correct for disparities (of the subsample for which serum was available) from 
German population statistics.
We analysed the following outcome variables in three separate models: (previous) HAV infection, hepatitis 
A vaccination and overall-HAV seropositivity. Specifically, our analysis assessed the influence of the following 
explanatory variables in relation to all three aforementioned outcomes: age, gender, place of residence, population 
size of the community of residence, (parental) socio-economic status, and migrant status. The appropriate dataset 
was extracted from the self-reported questionnaires of the German KiGGS survey.
For each parameter, the prevalence and odds ratio (OR) (univariable logistic regression) was calculated with a 
95% confidence interval (95% CI). When appropriate, the Wald test was used and a value of p < 0.05 was consid-
ered statistically significant. In logistic regression analyses, age (years) was used as continuous variable, all other 
variables were treated as categorical variables. The reference group was set to the lower or upper boundary for 
continuous or ordinal variables. For nominal variables, the reference group was set to the group having the lowest 
prevalence. For multivariable logistic regression, we started with a model including all parameters (full model) 
and excluded stepwise the least statistically significant parameter (backward elimination). Backward elimination 
was terminated after no parameter with a p-value of p > 0.05 remained in the stepwise-reduced model and the 
included parameters were considered to be statistically significant. For this purpose, an F-test was applied in order 
to compare different sub-models. Ultimately, all initially eliminated parameters were reintroduced separately into 
the final model, to test if they contribute meaningfully to the selected final model (F-test, p > 0.05).
Definition of German regions of places of residence (consolidated federal states). In our study, 
the place of residence of all 16 German federal states was consolidated into 6 areas: “North-West”, “Central-West”, 
“South-West”, “North-East”, “Central-East”, and “Berlin”, respectively.
North-West included the federal states Bremen, Hamburg, Lower Saxony, and Schleswig-Holstein, 
Central-West North Rhine-Westphalia, and Hesse, South-West Rhineland-Palatinate, Saarland, 
Baden-Wuerttemberg, and Bavaria, North-East Mecklenburg Western-Pomerania, and Brandenburg, and 
Central-East Saxony-Anhalt, Saxony, and Thuringia, respectively.
Definition of categories for the population size of the community of residence. The population 
size of the community of residence was categorised into 4 sizes (“rural area” (<5,000), “small town” (5,000–
<20,000), “medium-sized town” (20,000–<100,000), and “large town” with >=100,000 residents, respectively).
Definition of categories for socio-economic status. Information on the socio-economic status was 
grouped into 3 categories: “low”, “medium”, and “high” according to Lange M. et al.32.
Definition of categories for migration status. The migration status was categorised into “Non-migrant”, 
“One-sided”, and “Two-sided” migrant, respectively. For non-migrants none of the parents had immigrated to 
Germany. A one-sided migrant had one of the parents that immigrated to Germany. For a two-sided migrant 
the child itself and one of the parents immigrated or alternatively, both of the parents immigrated to Germany33.
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Ethics Statement and informed consent. This observational epidemiological study was approved by the 
Federal Office for Data Protection and by the ethics committee of Charité University Medicine, Berlin, Germany. 
Parents of the participants and all adolescents aged 14–17 years signed the written informed consent to the 
KiGGS study and the laboratory testing of their blood samples.
Results
Study response, and availability of vaccination cards and serum samples. Of 28,299 randomly 
selected study participants, 17,640 responded and also completed the provided questionnaire. The response rate 
of 66% and the analysis of non-response are detailed elsewhere23. Vaccination cards were available for 16,325 
(93%) participants. HAV serology was intended only for study participants aged 3 years and older (n = 14,835) 
and among these, a total of 13,063 (88%) samples were tested for anti-HAV antibodies. Both, serum sample and 
vaccination card were available for 12,249 (82%) out of all 14,835 study participants aged 3–17 years (Fig. 1).
Seroprevalence of anti-HAV antibodies in children and adolescents. Of 13,063 children and ado-
lescents tested for anti-HAV antibodies, 1,880 (14%) were found to be seropositive (>=20 IU/L). A histogram 
depicting the distribution of the 13,063 analysed anti-HAV antibody test results is shown in the supplement 
(Supplementary Fig. S1).
The weighted overall seroprevalence for anti-HAV antibodies in the German population aged 3–17 years 
was 13% (95% CI: 12–14%). Seroprevalence was strongly correlated with increasing age (Fig. 2, Supplementary 
Table S1). A significantly higher seroprevalence was observed in children or adolescents with a two-sided migra-
tion status as compared to non-migrants and one-sided migrants, respectively. In addition, seroprevalence dif-
fered at the regional level, with a notably high prevalence in Central-East Germany. Seroprevalence did not differ 
significantly by gender, community size and socio-economic status (Table 1).
In a weighted multivariable model, increasing age, having a high socio-economic status, a one-sided or a 
two-sided migration status, and living outside of North-West Germany was independently associated with HAV 
seropositivity (Table 1).
Seropositivity may have resulted either from HAV infection or hepatitis A vaccination. Of all 1,880 seroposi-
tive tested individuals 1,395 (74%) were vaccinated against hepatitis A, 360 (19%) were not vaccinated but sero-
positive, and 125 (7%) had an unknown vaccination status.
Accordingly, we also assessed HAV infections and hepatitis A vaccinations in separate analyses with a restric-
tion to those 12,249 participants with both, available vaccination card and serum sample test result.
HAV infections in children and adolescents. No hepatitis A vaccination was recorded in 10,785 (88%) 
of the 12,249 participants with available vaccination card and serum sample test result. However, 360 (3%) of the 
Figure 1. Flow chart and sample frequencies of participation by HAV serology and vaccination status.
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10,785 unvaccinated participants were found to be seropositive, thus indicating a previous HAV infection. This 
corresponds to a weighted prevalence of HAV infection among the unvaccinated, anti-HAV antibody-tested chil-
dren and adolescents of 3% (95% CI: 3–4%).
Increasing age correlated significantly with a higher prevalence of HAV infections in children and ado-
lescents. In addition, the prevalence of HAV infection was particularly high in children or adolescents with a 
two-sided migration status, a low socio-economic status and (on the regional level) among those living in Berlin 
or Central-East Germany. The prevalence of HAV infection did not differ significantly by gender and community 
size (Table 2).
In a weighted multivariable model, increasing age, having a two-sided migration status, and living in 
Central-East Germany was independently associated with a higher prevalence of HAV infection (Table 2).
Hepatitis A vaccinations in children and adolescents. Of 12,249 individuals with both, an available 
vaccination card and a test result for anti-HAV antibodies, 1,464 (12%) were vaccinated against hepatitis A (>=1 
shot of hepatitis A vaccine). Most of the 1,464 individuals vaccinated against hepatitis A were found to be sero-
positive (1,395, 95%). However, a total of 69 (5%) were seronegative (<20 IU/L) in spite of having a documented 
vaccination history.
The weighted prevalence of hepatitis A vaccination in German children and adolescents was 11% (95% CI: 
9–12%). Overall, the proportion of hepatitis A vaccinated individuals increased with age (p < 0.05). In addition, a 
significantly higher prevalence was observed in children or adolescents having a high or medium socio-economic 
status, respectively. Prevalence of hepatitis A vaccination differed at regional level with a notably high prevalence 
in Central-East Germany. Prevalence did not differ significantly by gender, community size and migration status 
(Table 3).
In a weighted multivariable model, increasing age, having a high socio-economic status, and living in 
South-West, North-East or Central-East Germany or Berlin, respectively, was independently associated with 
higher odds for hepatitis A vaccination (Table 3).
The analysis of aforementioned seronegative study participants (<20 IU/L) with a documented vaccination 
history (n = 69) revealed that 78% (n = 54) had been vaccinated with only 1 shot of hepatitis A vaccine (n = 22 
monovalent, n = 27 bivalent vaccine, respectively and n = 5 vaccine unknown). In contrast, among the sero-
positive study participants (>=20 IU/L) with a documented vaccination history (n = 1395), 15% (n = 207) had 
been vaccinated with 1 shot of hepatitis A vaccine (n = 119 monovalent, n = 77 bivalent vaccine, respectively and 
n = 11 vaccine unknown).
Discussion
The susceptibility to HAV infections is increasing in world regions with high socio-economic standards due to 
decreasing endemicity and the concomitant decline in naturally acquired immunity in childhood15,34,35. In order 
to provide a basis for an advanced prevention strategy, we quantified anti-HAV antibody levels in children and 
adolescents living in Germany and investigated epidemiological and socio-demographic aspects of HAV infec-
tions and hepatitis A vaccination.
In our nationwide, population-based, cross-sectional study, we demonstrated that 87% of German children 
and adolescents are susceptible to HAV. Moreover, we observed a significant age dependency, which reflects the 
cumulative life-time prevalence of HAV exposure or hepatitis A vaccination. These findings confirm the results 
of a previous report (Krumbholz et al.)36. Interestingly, in contrast to the aforementioned study (where males 
were found to have a significantly higher seroprevalence than females), we found a slightly higher seroprevalence 
in females instead of males, but this finding was not statistically significant (OR 1.10, 95% CI: 0.99–1.22). We 
Figure 2. Estimated (weighted) proportion of HAV-seropositive study participants by age (error bars indicate 
95% confidence intervals (95% CI), German children and adolescents, aged 3–17 years, n = 13,063). The dashed 
line depicts the estimated mean of the HAV-seroprevalence (13%). Serum samples of children aged 0–2 years 
were not requested. (The specific values per age including the respective 95% confidence intervals are provided 
in the supplement; Supplementary Table S1).
www.nature.com/scientificreports/
5ScIEnTIfIc RePoRtS |         (2018) 8:16696  | DOI:10.1038/s41598-018-34927-1
suppose that this observed difference may have resulted due to the different study designs and study populations 
(nationwide, population-based, cross-sectional survey vs. sera taken from German paediatric centres).
Beyond that, our study also separately analysed seropositivity due to hepatitis A vaccination and HAV infec-
tion with regard to socio-demographic determinants. To our knowledge, this is the first nationwide, representa-
tive study conducted in industrialised countries which investigated both essential aspects of the epidemiology of 
hepatitis A using serological and vaccination data.
Overall, HAV immunity was mainly due to hepatitis A vaccination rather than HAV infection (11% vs. 3%). 
The low proportion of naturally acquired immunity in children and adolescents reflects a very low level of HAV 
endemicity in Germany6,13,16,34. The multivariable model indicated that two-sided migration status and living 
in Central-East Germany are independently associated with HAV infection. We assume this is probably due to 
different travel behaviour (to HAV endemic areas) and/or origin from HAV endemic countries. In this regard, 
particularly migrants may travel more frequently to regions with lower socio-economic standards that are HAV 
endemic (e.g. Turkey, Balkan countries) to visit friends and relatives or are visited by their relatives living in 
HAV endemic areas, here particularly asymptomatic children may start (unnoticed) transmission chains4,37–41. 
However, there may be other possible differences than traveling to HAV endemic areas that have not been inves-
tigated in our study.
In regard to hepatitis A vaccinations we found that regional differences as well as a higher socio-economic 
status were independently associated in the multivariable analysis. This finding could indicate that parents with 
a higher socio-economic status are better informed about the protective value of hepatitis A vaccination and 
therefore more frequently request immunisations for their children (e.g. possibly in connection with travel to 
HAV endemic regions). The marked difference with significantly higher hepatitis A vaccination in the region 
“Central-East” (with the federal states Saxony-Anhalt, Saxony, and Thuringia) can be explained by local vaccina-
tion recommendations in the federal state Saxony. In Saxony, the Federal Committee on Vaccination recommends 
(since 2002) either a complete regimen of HAV/HBV combination vaccinations for all children aged 2–17 years, 
or alternatively, following a complete HBV immunisation regimen in the first two years of life, a (single) HAV 
vaccination for children aged 2–17 years42.
Characteristic (total no.)
(weighted) seroprevalence (weighted) univariable analysis (weighted) multivariable analysis
% (95% CI) Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Anti-HAV tested (13,063) 12.97 (11.76–14.29) — — — —
Age (yearly) — 1.12 (1.10–1.13) <0.001 1.11 (1.09–1.13) <0.001
Sex
   male (6,708) 12.46 (11.09–13.97) ref. — — —
   female (6,355) 13.52 (12.22–14.93) 1.10 (0.99–1.22) 0.085 — —
Place of residence
   North-West (1,641) 7.49 (5.96–9.02) ref. — ref. —
   Central-West (3,123) 10.32 (9.01–11.63) 1.42 (1.09–1.85) 0.009 1.36 (1.02–1.82) 0.034
   South-West (3,912) 14.22 (11.85–16.60) 2.05 (1.53–2.75) <0.001 2.08 (1.50–2.86) <0.001
   North-East (1,390) 14.02 (10.99–17.06) 2.01 (1.44–2.82) <0.001 2.14 (1.48–3.10) <0.001
   Central-East (2,609) 25.74 (20.73–30.75) 4.28 (3.04–6.03) <0.001 4.80 (3.33–6.93) <0.001
   Berlin (388) 14.31 (10.03–18.59) 2.06 (1.36–3.12) 0.001 1.81 (1.17–2.80) 0.008
Populationsize of municipality
   <5,000 (rural area) (2,875) 14.42 (10.03–18.08) ref. — — —
   5,000–<20,0000 (small town) (3,470) 13.36 (10.83–15.89) 0.92 (0.60–1.39) 0.677 — —
   20,000–<100,0000 (medium-sized 
town) (3,778) 11.75 (9.95–13.55) 0.79 (0.53–1.17) 0.242 — —
   >100,000 (large town) (2,940) 12.94 (11.14–14.75) 0.88 (0.60–1.30) 0.528 — —
Socio-economic status
   low (3,415) 12.43 (10.61–14.26) ref. — ref. —
   medium (6,037) 11.85 (10.43–13.27) 0.95 (0.82–1.10) 0.462 1.02 (0.88–1.18) 0.795
   high (3,292) 14.25 (12.45–16.05) 1.17 (0.98–1.40) 0.087 1.44 (1.20–1.74) <0.001
   unknown (319) — — — — —
Migration status
   Non-migrant (10,203) 11.81 (10.38–13.24) ref. — ref. —
   One-sided (879) 12.58 (9.85–15.31) 1.08 (0.83–1.40) 0.586 1.32 (1.01–1.73) 0.043
   Two-sided (1,928) 18.24 (16.07–20.41) 1.67 (1.40–1.99) <0.001 1.93 (1.57–2.36) <0.001
   unknown (53) — — — — —
Table 1. Overall HAV-seroprevalence: estimated (weighted) prevalence of HAV-specific antibodies in German 
children and adolescents (aged 3–17 years) by demographic characteristics and (weighted) results of univariable 
and multivariable analyses (n = 13,063). All study participants with an available HAV serology are included in 
the analysis (see Fig. 1).
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Our study provides a snapshot of the situation surveyed ten years ago and we cannot exclude that the situation 
has changed in the past decade. However, we are assuming that possible changes would be rather modest (towards 
an even lower HAV seropositivity) and likely not vary the interpretation of demographic and epidemiological 
factors associated with the outcomes seropositivity, vaccination coverage and infection risks. In addition, we can-
not preclude a potential cohort effect (e.g. specific travel preferences or the proportion and origin of children or 
adolescents born abroad). In order to reflect such possible changes (which may influence hepatitis A vaccination 
and HAV infection) a follow-up study would be useful to conduct in the years ahead.
In recent years, several food-borne outbreaks of hepatitis A have been described in Germany and other European 
countries43–46. These outbreaks affected mostly adults, possibly because children are more often asymptomatically 
infected. We assume that these incidents impacted the seroprevalence only marginally. However, we hope that such 
reports have been increasing awareness and resulted also in higher vaccination uptakes in children and adolescents.
Migration is another important factor to consider that may has been changing the seroprevalence of children 
and adolescents living in Germany. Particularly from 2015 to 2016 a larger influx of asylum seekers to Germany 
was reported6. Challenging travel conditions, and the high exposure risk related to poor hygienic standards when 
asylum seekers have fled to Germany, resulted in increased hepatitis A notifications. The increased hepatitis A 
notifications mainly related to children of asylum seekers shortly after arrival to Germany. Importantly, concern-
ing German residents, no further transmission of HAV has been reported in this regard6. Assuming that a major-
ity of asylum seekers successfully applied for asylum and is residing in Germany now, this influx would change the 
point estimate of a nationwide, population-based, cross-sectional survey. A recent study reported an anti-HAV 
antibody prevalence of 70% for this particular group (asylum seeking children <18 years with arrival to Germany 
in 2015)47,48. Although the prevalence is much higher than the observed overall seroprevalence in the German 
population aged 3–17 years (13%) it would only marginally increase the point estimate.
The observed overall response rate of 66% of the German KiGGS survey (“German Health Interview and 
Examination Survey for Children and Adolescents”) was in the range of comparable epidemiological studies49. 
To account for possible sampling bias and to ensure representativeness for children and adolescents living in 
Characteristic (total no.)
(weighted) prevalence (weighted) univariable analysis (weighted) multivariable analysis
% (95% CI) Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Anti-HAV tested and vaccination card 
available (10,785) 3.24 (2.87–3.66) — — — —
Age (yearly) — 1.08 (1.04–1.11) <0.001 1.07 (1.04–1.11) <0.001
Sex
   male (5,552) 2.91 (2.45–3.46) ref. — — —
   female (5,233) 3.59 (3.06–4.20) 1.24 (0.99–1.56) 0.065 — —
Place of residence
   North-West (1,423) 2.42 (1.71–3.42) ref. — ref. —
   Central-West (2,676) 3.63 (3.04–4.32) 1.51 (1.02–2.26) 0.042 1.31 (0.87–1.97) 0.193
   South-West (3,228) 3.00 (2.32–3.74) 1.23 (0.80–1.89) 0.354 1.16 (0.75–1.80) 0.508
   North-East (1,174) 2.67 (1.86–3.82) 1.10 (0.66–1.85) 0.704 1.38 (0.80–2.38) 0.242
   Central-East (1,954) 4.32 (3.09–6.01) 1.82 (1.11–2.99) 0.019 2.30 (1.37–3.88) 0.002
   Berlin (330) 5.03 (3.00–8.32) 2.13 (1.12–4.07) 0.021 1.76 (0.90–3.45) 0.097
Populationsize of municipality
   <5,000 (rural area) (2,382) 3.05 (2.24–4.13) ref. — — —
   5,000–<20,0000 (small town) (2,880) 2.85 (2.10–3.85) 0.93 (0.60–1.45) 0.759 — —
   20,000–<100,0000 (medium-sized 
town) (3,147) 3.13 (2.63–3.73) 1.03 (0.72–1.48) 0.873 — —
   >100,000 (large town) (2,376) 3.95 (3.21–4.85) 1.31 (0.89–1.92) 0.165 — —
Socio-economic status
   low (2,792) 4.18 (3.36–5.19) ref. — — —
   medium (5,083) 2.68 (2.20–3.26) 0.63 (0.47–0.85) 0.002 — —
   high (2,708) 2.58 (2.04–3.25) 0.61 (0.44–0.85) 0.003 — —
   unknown (202) — — — — —
Migration status
   Non-migrant (8,542) 2.28 (1.94–2.68) ref. — ref. —
   One-sided (726) 2.97 (1.92–4.58) 1.31 (0.80–2.15) 0.281 1.45 (0.88–2.39) 0.148
   Two-sided (1,479) 7.76 (6.34–9.48) 3.60 (2.76–4.70) <0.001 3.84 (2.92–5.04) <0.001
   unknown (38) — — — — —
Table 2. HAV-infections: estimated (weighted) prevalence of HAV-specific antibodies due to HAV infection in 
German children and adolescents (aged 3–17 years) by demographic characteristics and (weighted) results of 
univariable and multivariable analyses (n = 10,785). The results refer to a subsample of study participants with 
HAV serology but who have not been vaccinated (see Fig. 1).
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Germany an analysis of non-response was conducted and a weighting factor was introduced in order to correct 
the sample’s deviations from the (German) population structure22.
The vaccination status in our study population was assessed using records in vaccination cards. Although 
this is a reasonable method, we are aware that those records occasionally might be incomplete. In such cases, 
this would have led to a misclassification and overestimation of HAV infected individuals. Such overestimation 
might be bypassed using specific serological methods (with HAV non-structural epitopes) which have been very 
recently described50,51. Thus, such a new technique could then also be implemented in a follow-up study.
In our study, we did not consider the completeness of the vaccination sequence among the study participants. 
Depending on the vaccine, two or more shots are recommended for a long-term protection against infections of 
HAV52–55. We found 69 (5%) participants being seronegative (anti-HAV-IgG titres of <20.0 IU/L) in spite of a doc-
umented vaccination history. The majority of these individuals had been vaccinated with one shot of hepatitis A 
vaccine only, underlining previous investigations that one dose of vaccine induces protective anti-HAV-IgG titres 
in approximately 95% of the vaccinees and only after a booster vaccination this proportion reaches 100%56–62.
In response to the steady decline in naturally acquired HAV immunity especially in children in many parts of 
the world, some countries have introduced universal childhood vaccination programmes in recent years9,17–20,63,64. 
The WHO suggests a vaccination strategy according to the HAV endemicity of the particular region65–68. In this 
context, for areas with a very low HAV endemicity, such as Germany, hepatitis A vaccination is currently recom-
mended for high-risk groups only34,69.
The German Standing Committee on Vaccination recommends vaccination against hepatitis A for all individ-
uals traveling to HAV endemic areas in addition to other risk groups such as men having sex with men (MSM) 
and persons with an occupational risks of HAV infection, respectively21. In Germany, travel-related vaccinations 
are not generally reimbursed. However, most German health insurance companies offer travel-related vaccina-
tions as (free) incentives70.
The results of our study argue for targeting children and adolescents with a lower socio-economic status or a 
two-sided migration background more explicitly. Hence, health insurance companies, general practitioners and 
travel agencies among others could help to communicate the protection of hepatitis A vaccination to prospec-
tive travellers to endemic regions and recommend vaccination accordingly even (years) in advance. In addition, 
Characteristic (total no.)
(weighted) prevalence (weighted) univariable analysis (weighted) multivariable analysis
% (95% CI) Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Vaccination card accessible (12,249) 10.51 (9.31–11.84) — — — —
Age (yearly) — 1.13 (1.11–1.15) <0.001 1.12 (1.09–1.13) <0.001
Sex
   male (6,282) 10.30 (8.95–11.84) ref. — — —
   female (5,967) 10.73 (9.51–12.08) 1.05 (0.94–1.17) 0.423 — —
Place of residence
   North-West (1,503) 5.57 (4.34–7.12) ref. — ref. —
   Central-West (2,877) 7.12 (5.98–8.46) 1.30 (0.94–1.80) 0.110 1.29 (0.94–1.79) 0.119
   South-West (3,655) 12.08 (9.91–14.65) 2.33 (1.65–3.29) <0.001 2.33 (1.63–3.33) <0.001
   North-East (1,335) 12.11 (9.06–16.00) 2.34 (1.54–3.55) <0.001 2.11 (1.37–3.25) 0.001
   Central-East (2,516) 23.66 (19.13–28.87) 5.26 (3.61–7.66) <0.001 4.99 (3.38–7.39) <0.001
   Berlin (363) 8.95 (6.61–12.02) 1.67 (1.10–2.54) 0.017 1.66 (1.06–2.61) 0.028
Populationsize of municipality
   <5,000 (rural area) (2,763) 12.44 (8.16–16.72) ref. — — —
   5,000–<20,0000 (small town) (3,298) 11.29 (8.79–13.79) 0.90 (0.56–1.43) 0.642 — —
   20,000–<100,0000 (medium-sized 
town) (3,505) 9.15 (7.44–10.86) 0.71 (0.45–1.10) 0.127 — —
   >100,000 (large town) (2,683) 9.78 (7.87–11.69) 0.76 (0.49–1.19) 0.235 — —
Socio-economic status
   low (3,103) 8.56 (6.96–10.49) ref. — ref. —
   medium (5,767) 10.26 (8.94–11.75) 1.22 (1.01–1.48) 0.044 1.16 (0.95–1.41) 0.149
   high (3,156) 12.83 (11.11–14.77) 1.57 (1.24–1.99) <0.001 1.67 (1.33–2.09) <0.001
   unknown (223) — — — — —
Migration status
   Non-migrant (9,738) 10.64 (9.31–12.13) ref. — — —
   One-sided (819) 11.07 (8.69–14.00) 1.05 (0.79–1.39) 0.754 — —
   Two-sided (1,649) 9.69 (7.92–11.81) 0.90 (0.72–1.13) 0.357 — —
   unknown (43) — — — — —
Table 3. Hepatitis A vaccination: estimated (weighted) prevalence of hepatitis A vaccination in German 
children and adolescents (aged 3–17 years) by demographic characteristics and (weighted) results of univariable 
and multivariable analysis (n = 12,249). The results refer to a subsample of study participants with HAV 
serology and accessible vaccination cards (see Fig. 1).
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information should be provided on possible infection risks (particularly by asymptomatic children) during family 
visits to Germany from relatives living in HAV endemic areas.
As travel-related vaccinations are reimbursed by most German health insurance companies, not only informa-
tion on the benefit of vaccination but also easier reimbursements could presumably increase vaccination coverage, 
especially in children and adolescents with a lower socio-economic status or a two-sided migration background.
Importantly, such a targeted vaccination policy would be beneficial not only for protecting this particular 
at-risk group, but would also reduce secondary infections and hepatitis A outbreaks in schools, kindergartens or 
day care facilities that may occur as a result of asymptomatic infected children or adolescents after returning from 
HAV endemic areas37,38,40,71.
In summary, our study reflects central aspects of the epidemiology of hepatitis A in German children and ado-
lescents and provides arguments for a refined hepatitis A prevention strategy. Although the study was conducted 
in children and adolescents living in Germany, we believe many other low-incidence countries have a comparable 
epidemiological situation and our recommendation apply as well in these countries.
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